Fiala

Peptide library › Cancer & imaging

Lutetium Lu-177 vipivotide tetraxetan

Also known as Pluvicto, 177Lu-PSMA-617

FDA-approved drugCancer & imaging

Targeted radiation therapy for advanced prostate cancer that carries the PSMA protein.

What people use it for

What Lutetium Lu-177 vipivotide tetraxetan does in the body

A small molecule that binds PSMA, a protein on most prostate cancer cells, carrying radioactive lutetium-177 to kill them.

Strength of evidence

Strong: the VISION trial improved survival; PSMAfore supported earlier use.

Look up the evidence

Live searches of official databases. New to the terms? See the glossary.

Reported side effects & risks

Who should avoid it or take extra care

Not a complete list. Check with a doctor or pharmacist about your own health and medicines.

Regulatory status

FDA-approved in 2022, with its use widened in 2025 to some patients before chemotherapy. Specialist centres only.

How it's taken

Route: Infusion into a vein, every 6 weeks for up to 6 doses

How long it lasts (half-life): Lutetium-177 loses half its radioactivity every 6.7 days

Storage

Stored and prepared by the pharmacy or clinic, following the product label.

Latest research & news

Picked automatically from PubMed, ClinicalTrials.gov and the FDA, and updated daily. Early, lab and animal studies often don't carry over to people.

Keep track of Lutetium Lu-177 vipivotide tetraxetan privately

Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.

Open Lutetium Lu-177 vipivotide tetraxetan in Fiala How to install
Not medical advice. This page is general education. Talk to a qualified clinician before starting, stopping or changing any treatment.

More in Cancer & imaging